Effects of Intradermal Botulinum Toxin Injections on Herpes Zoster Related Neuralgia

References

• Anant P, Mohamad G, Uwe W. Herpes zoster: a review of clinical manifestations and management. Viruses. 2022;14(2):192.
   PubMed Web of Science ®Google Scholar
• Chen YT, Wang HH, Wang TJ, et al. Early application of low-level laser may reduce the incidence of postherpetic neuralgia (PHN). J Am Acad Dermatol. 2016;75(3):572–577. doi:10.1016/j.jaad.2016.03.050
   PubMed Web of Science ®Google Scholar
• Wollina U, Machetanz J. Herpes zoster und postzosterische Neuralgie. Der Hautarzt. 2016;67:653–665. doi:10.1007/s00105-016-3834-y
   PubMed Web of Science ®Google Scholar
• Forbes HJ, Bhaskaran K, Thomas SL, et al. Quantification of risk factors for postherpetic neuralgia in herpes zoster patients. Neurology. 2016;87:94–102. doi:10.1212/WNL.0000000000002808
   PubMed Web of Science ®Google Scholar
• Dosenovic S, Jelicic Kadic A, Miljanovic M, et al. Interventions for neuropathic pain: an overview of systematic reviews. Anesth Analg. 2017;125(2):643–652. doi:10.1213/ANE.0000000000001998
   PubMed Web of Science ®Google Scholar
• Shackleton T, Ram S, Black M, Ryder J, Clark GT, Enciso R. The effi- cacy of botulinum toxin for the treatment of trigeminal and postherpetic neuralgia: a systematic review with meta-analyses. Oral Surg Oral Med Oral Pathol Oral Radiol. 2016;122(1):61–71. doi:10.1016/j.oooo.2016.03.003
   PubMed Web of Science ®Google Scholar
• Schantz EJ, Johnson EA. Botulinum toxin: the story of its development for the treatment of human disease. Perspect Biol Med. 1997. doi:10.1353/pbm.1997.0032
   PubMed Web of Science ®Google Scholar
• Nicolae PM, Cristina B, Gabriela IM, et al. Botulinum toxin use for modulating neuroimmune cutaneous activity in psoriasis. Medicina. 2022;58(6):813. doi:10.3390/medicina58060813
   PubMedGoogle Scholar
• Popescu MN, Petca RC, Beiu C, et al. Efficiency of different preparations of botulinum toxin type A, Xeomin and Dysport, in the management of spastic upper limb after stroke. Rehabilitation. 2019;70(10):3490–3494.
   Google Scholar
• Intiso D, Basciani M, Santamato A, Intiso M, Di Rienzo F. Botulinum toxin type A for the treatment of neuropathic pain in neuro-rehabilitation. Toxins. 2015;7:2454–2480. doi:10.3390/toxins7072454
   PubMed Web of Science ®Google Scholar
• Vincent H, Sebastien S, Valeria M. Efficacy and safety of botulinum A toxin for the treatment of chronic peripheral neuropathic pain: a systematic review of randomized controlled trials and meta-analysis. Eur J Pain. 2022;26:980–990. doi:10.1002/ejp.1941
   PubMed Web of Science ®Google Scholar
• Michael A, Sabine P, Sharma Shashi K, et al. Preclinical evidence for the role of Botulinum Neurotoxin A (BoNT/A) in the treatment of peripheral nerve injury.microorganisms. 2022;10(5):886. doi:10.3390/microorganisms10050886
   PubMed Web of Science ®Google Scholar
• Anupam DG, Suzanne E, Jessica S, et al. A systematic review and meta-analysis of efficacy of botulinum toxin A for neuropathic pain. Toxins. 2022;14(1):36. doi:10.3390/toxins14010036
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Apalla Z, Panagiotidou D, et al. Severe post-herpetic neuralgia successfully treated with botulinum toxin A: three case reports. Acta Derm Venereol. 2009;89:214–215. doi:10.2340/00015555-0609
   PubMed Web of Science ®Google Scholar
• Egeo G, Fofi L, Barbanti P. Botulinum neurotoxin for the treatment of pain. Front Neurol. 2020;11. doi:10.3389/fneur.2020.00716
   PubMed Web of Science ®Google Scholar
• Woolf CJ, Shotland P, Coggeshall RE. Peripheral nerve injury triggers central sprouting of myelinated afférents. Nature. 1992;335:75–78. doi:10.1038/355075a0
   Google Scholar
• Kost RG, Strauss SE, Wood AJJ. post herpetic neuralgia pathogenesis, treatment, and prevention: a review article. N Engl J Med. 1996;4:32–40. doi:10.1056/NEJM199607043350107
   Google Scholar
• Till W, Chris P, Andrea R-D. The capsaicin 8% patch for neuropathic pain in clinical practice: a retrospective analysis. Pain Med. 2013;14:1202–1211. doi:10.1111/pme.12143
   PubMed Web of Science ®Google Scholar
• Tyring SK. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol. 2007;57:136–142. doi:10.1016/j.jaad.2007.09.016
   PubMed Web of Science ®Google Scholar
• Kelin H, Fengjia N, Yi H, et al. Efficacy and safety of electroacupuncture for pain control in herpes zoster: a systematic review and meta-analysis. Evid Based Complement Alternat Med. 2022;2022:4478444. doi:10.1155/2022/4478444
   PubMedGoogle Scholar
• Ruiz HC, Bermejo P. Botulinum toxin type A in the treatment of neuropathic pain in a case of postherpetic neuralgia. Neurologia. 2008;23:259–262.
   PubMed Web of Science ®Google Scholar
• Lorenzo L, de Sire A, Arianna F, et al. Multidimensional effectiveness of botulinum toxin in neuropathic pain: a systematic review of randomized clinical trials. Toxins. 2022;14(5):308. doi:10.3390/toxins14050308
   PubMed Web of Science ®Google Scholar
• Mehrdad T, Meghdad S, Ali S, et al. The effect of intradermal botulinum toxin a injections on painful diabetic polyneuropathy. Diabetes Metab Syndr. 2020;14:1823–1828. doi:10.1016/j.dsx.2020.09.019
   PubMed Web of Science ®Google Scholar
• Waranaree W, Vasanop V. Botulinum toxin type A for the treatment of skin ulcers: a review article. Toxins. 2022;14(6):406. doi:10.3390/toxins14060406
   PubMed Web of Science ®Google Scholar
• Axel WM, Michelle M, Kruger Tillmann HC, et al. Treatment of depression with botulinum toxin. Toxins. 2022;14(6):383. doi:10.3390/toxins14060383
   PubMed Web of Science ®Google Scholar
• Fen P, Siqi Z, Xuan Z, et al. Calcitonin gene-related peptide upregulates IL-17A and IL-22 in γδ-T cells through the paracrine effect of Langerhans cells on LC/γδ-T co-culture model. J Neuroimmunol. 2022;364:577792. doi:10.1016/j.jneuroim.2021.577792
   PubMed Web of Science ®Google Scholar
• Liu HT, Tsai SK, Kao MC, Hu JS. Botulinum toxin A relieved neuropathic pain in a case of post-herpetic neuralgia. Pain Med. 2006;7:89–91. doi:10.1111/j.1526-4637.2006.00100.x
   PubMed Web of Science ®Google Scholar
• Apalla Z, Sotiriou E, Lallas A, Lazaridou E, Ioannides D. Botulinum toxin A in postherpetic neuralgia: a parallel, randomized, double blind, single-dose, placebo-controlled trial. Clin J Pain. 2013;29:857–864. doi:10.1097/AJP.0b013e31827a72d2
   PubMed Web of Science ®Google Scholar
• Chen S. Clinical uses of botulinum neurotoxins: current indications, limitations and future developments. Toxins. 2012;4:913–939. doi:10.3390/toxins4100913
   PubMed Web of Science ®Google Scholar
• Ababneh OH, Cetinkaya A, Kulwin DR. Long-term efficacy and safety of botulinum toxin A injections to treat blepharospasm and hemifacial spasm. Clin Exp Ophthalmol. 2014;42:254–261. doi:10.1111/ceo.12165
   PubMed Web of Science ®Google Scholar
• Carmichael NME, Dostrovsky JO, Charlton MP. Peptide-mediated transdermal delivery of botulinum neurotoxin type A reduces neurogenic inflammation in the skin. Pain. 2010;149:316–324. doi:10.1016/j.pain.2010.02.024
   PubMed Web of Science ®Google Scholar